Paul Bradley
Family · Muskegon, MINPI 1164153672
Payments from drug & device makers
Across 99 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$368
- Novo Nordisk$272
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
- Teva Pharmaceuticals USA, Inc.$149
- Vanda Pharmaceuticals Inc.$86
- Bayer$73
- plus $757 from 21 others
What the payments were for
- Food & beverage$1,859100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $368 |
| Novo Nordisk | 14 | $272 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $155 |
| Teva Pharmaceuticals USA, Inc. | 7 | $149 |
| Vanda Pharmaceuticals Inc. | 3 | $86 |
| Bayer | 5 | $73 |
| Lundbeck LLC | 3 | $71 |
| Exact Sciences | 3 | $63 |
| Merck | 3 | $61 |
| Pfizer | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| GSK | 3 | $56 |
| Astellas Pharma US Inc | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| USWM, LLC | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Tempus AI, Inc | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Amgen | 1 | $16 |
| Novartis | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| AstraZeneca | 1 | $14 |
How this compares
$1,859 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 83 | $101,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $89,678 |
| RexultiBrexpiprazole | 37 | $82,042 |
| EliquisApixaban | 71 | $81,568 |
| OtezlaApremilast | 11 | $52,996 |
| FarxigaDapagliflozin Propanediol | 51 | $51,500 |
| JardianceEmpagliflozin | 50 | $37,502 |
| CreonLipase/Protease/Amylase | 13 | $36,665 |
| JanuviaSitagliptin Phosphate | 30 | $31,345 |
| MounjaroTirzepatide | 27 | $27,834 |
| RybelsusSemaglutide | 20 | $21,629 |
| EntrestoSacubitril/Valsartan | 27 | $19,388 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $16,259 |
| XareltoRivaroxaban | 17 | $12,349 |
| OzempicSemaglutide | 13 | $11,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $38 | $129,788110 claims |
| GSKTrelegy Ellipta | $56 | $89,678116 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $58 | $82,04237 claims |
| PfizerEliquis | $60 | $81,56871 claims |
| AmgenOtezla | $16 | $52,99611 claims |
| AstraZenecaFarxiga | $14 | $51,50051 claims |
| AbbVieCreon | $368 | $36,66513 claims |
| Novo NordiskRybelsus, Ozempic | $272 | $33,59833 claims |
| MerckJanuvia | $61 | $31,34530 claims |
| NovartisEntresto | $15 | $19,38827 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $10,29617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Muskegon
- Elaine EngelsmanMuskegon$27K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.